Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus PT from Brokerages

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $25.60.

A number of research analysts recently commented on the company. Oppenheimer increased their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an "outperform" rating in a research note on Thursday, November 14th. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, December 10th.

Astria Therapeutics Price Performance

ATXS stock traded up $0.09 during midday trading on Thursday, reaching $9.45. The company had a trading volume of 283,925 shares, compared to its average volume of 589,674. Astria Therapeutics has a 1 year low of $5.94 and a 1 year high of $16.90. The company has a market capitalization of $533.30 million, a P/E ratio of -4.52 and a beta of 0.67. The firm has a 50-day moving average price of $10.70 and a 200-day moving average price of $10.69.

Hedge Funds Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its stake in shares of Astria Therapeutics by 6.9% during the second quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company's stock valued at $1,266,000 after purchasing an additional 8,965 shares during the period. Panagora Asset Management Inc. grew its holdings in Astria Therapeutics by 104.7% in the 2nd quarter. Panagora Asset Management Inc. now owns 30,926 shares of the biotechnology company's stock worth $281,000 after acquiring an additional 15,816 shares during the last quarter. Rhumbline Advisers increased its position in shares of Astria Therapeutics by 4.1% in the second quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company's stock valued at $595,000 after acquiring an additional 2,556 shares during the period. Quest Partners LLC increased its position in shares of Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 3,112 shares during the period. Finally, ClariVest Asset Management LLC bought a new position in shares of Astria Therapeutics during the second quarter valued at about $731,000. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.